Beta Blocker vs. ACE Inhibitor: What’s the Difference?

Beta blockers and ACE inhibitors both lower blood pressure and protect the heart, but they do it through completely different mechanisms and are suited to different clinical situations. Beta blockers slow the heart rate and reduce the force of each heartbeat by blocking the effects of adrenaline, while ACE inhibitors relax blood vessels by interrupting the hormonal chain that makes them constrict. That distinction shapes everything from which conditions each drug treats best, to the side effects you can expect, to who should avoid them entirely.

How Each Drug Works

Beta blockers target receptors on the heart and blood vessels that respond to adrenaline and related stress hormones. When those receptors are blocked, the heart beats more slowly and with less force, and blood vessels relax somewhat. This lowers blood pressure, reduces the heart’s demand for oxygen, and helps regulate abnormal heart rhythms. Three generations of beta blockers have been developed: older nonselective versions that block receptors throughout the body, cardioselective versions that primarily target the heart, and newer vasodilating beta blockers that also actively widen blood vessels.

ACE inhibitors work on a different system entirely. Your body produces a hormone called angiotensin II that constricts blood vessels, promotes salt retention, and can thicken heart muscle over time. ACE inhibitors block the enzyme that creates angiotensin II, tipping the balance away from those effects and toward vasodilation and salt excretion. They also slow the breakdown of bradykinin, a substance that helps blood vessels relax. The net result is lower blood pressure achieved by reducing resistance in the blood vessels, without speeding up the heart rate.¹

Where Each Drug Fits Best

Because they work differently, these two drug classes have overlapping but distinct sweet spots. Beta blockers are used to manage arrhythmias, treat chest pain from angina, and support the heart after a heart attack, in addition to lowering blood pressure. ACE inhibitors provide strong protection for the heart after a heart attack and are a go-to choice for congestive heart failure, particularly when the heart’s pumping ability has weakened.²

After a heart attack specifically, both drugs offer survival benefits, but the evidence supports them for slightly different reasons. Beta blockers reduce the risk of dying from a cardiovascular cause and lower the chance of having another heart attack. ACE inhibitors, meanwhile, provide an overall survival benefit particularly in people who develop signs of weakened heart function after the event.³ In practice, many heart attack survivors end up on both drugs at once, because the benefits don’t fully overlap.

For plain high blood pressure without other complications, clinical guidelines have shifted over the years. Beta blockers were once considered a first-line option but have been somewhat deprioritized in many guidelines in favor of ACE inhibitors, calcium channel blockers, and diuretics. Beta blockers are still a perfectly reasonable choice when there is a specific reason to use one, such as a fast resting heart rate, a history of arrhythmia, or angina.

Side Effects That Set Them Apart

The side-effect profiles of these two classes are almost entirely different, which often makes the choice between them come down to what a given person tolerates best.

Beta blockers commonly cause fatigue, cold hands and feet, and sometimes dizziness. Because they slow the heart, they can make exercise feel harder, since the heart cannot speed up as much in response to physical effort. Older nonselective beta blockers can also trigger airway constriction, which is why they are generally avoided in people with asthma or severe chronic lung disease. Sexual side effects, particularly erectile dysfunction, are another well-known complaint.

ACE inhibitors have their own hallmark side effect: a persistent, dry cough. The cough is thought to stem from bradykinin buildup, the same mechanism that helps these drugs relax blood vessels.⁴ There is evidence that susceptibility to this cough is partly genetic.⁵ It affects a meaningful minority of users and is the single most common reason people switch off an ACE inhibitor. A rarer but more serious risk is angioedema, a sudden swelling of the face, lips, or throat that requires immediate medical attention. ACE inhibitors can also raise potassium levels and cause a temporary bump in creatinine, a marker of kidney function, which is why blood work is typically checked after starting them.⁶

Metabolic Effects and Diabetes Risk

One underappreciated difference is how these drugs affect metabolism. Conventional beta blockers tend to worsen insulin resistance and raise triglyceride levels in a dose-dependent way, meaning the higher the dose, the larger the effect.⁷ Over time, this translates into a higher rate of new-onset diabetes among people taking older beta blockers compared to those on ACE inhibitors, calcium channel blockers, or ARBs, which have neutral or even slightly beneficial effects on insulin sensitivity.⁸

This matters most for people who are already at risk of developing type 2 diabetes, such as those who are overweight or have prediabetes. It does not mean beta blockers are dangerous for these patients, but it is one factor that can tip a prescriber toward an ACE inhibitor when both drugs would otherwise be reasonable choices. Newer vasodilating beta blockers like carvedilol and nebivolol appear to have less metabolic downside than older agents, though the evidence base is thinner.

Kidney Protection

ACE inhibitors have long been viewed as kidney-friendly, especially in people with diabetes. The logic makes sense: by dilating the tiny blood vessels leaving the kidney’s filtering units, they reduce the pressure inside those filters and slow the leak of protein into the urine, which is an early sign of kidney damage. They are frequently prescribed to patients with type 2 diabetes for this reason.

The picture is a bit more complicated than the reputation suggests, though. Much of the evidence for ACE inhibitors slowing kidney disease progression in type 2 diabetes comes from relatively small trials that tracked surrogate markers like protein in the urine, rather than hard endpoints like progression to kidney failure.⁹ That does not mean the protection is not real, but the evidence is less ironclad than is sometimes assumed. Beta blockers do not carry the same kidney-specific reputation, though they lower blood pressure just as effectively, and controlling blood pressure itself is one of the most important things you can do to protect the kidneys.

Blood Pressure Response and Ethnicity

People of African descent tend to have a smaller blood-pressure-lowering response to both beta blockers and ACE inhibitors compared to people of European descent, though the response is still clinically meaningful in both groups.¹⁰ In the large ASCOT trial, Black patients allocated to the beta blocker atenolol had a notably weaker blood pressure response compared to white patients, and also showed a lesser response when the ACE inhibitor perindopril was added as second-line therapy. South Asian patients, by contrast, had a larger blood pressure response to the addition of perindopril than white patients did.¹¹

These differences are population-level trends, not absolute rules for any individual. A Black patient may respond perfectly well to an ACE inhibitor, and a white patient may not. But the trends do influence prescribing guidelines in some countries, where calcium channel blockers or diuretics are recommended as first-line options for Black patients with hypertension, with ACE inhibitors and beta blockers reserved for add-on therapy or cases where another indication exists.

Pregnancy

This is one area where the distinction between the two drug classes could not be sharper. ACE inhibitors are well established as harmful during the second and third trimesters of pregnancy, where they can cause kidney shutdown in the developing fetus. More recent evidence suggests the risk extends to the first trimester as well. Data from a large European registry found that ACE inhibitor use during the first trimester was associated with roughly a threefold increase in the risk of congenital anomalies.¹² A systematic review of case reports found that over half of newborns exposed to ACE inhibitors showed no complications, but among those exposed to the related ARB class, outcomes were worse, with neonatal complications including kidney failure, low amniotic fluid, and growth restriction.¹³ The practical upshot: women who are pregnant or planning to become pregnant should avoid ACE inhibitors entirely.¹⁴

Beta blockers are not risk-free in pregnancy either. Some are associated with slowed fetal growth and low birth weight, and they can lower the newborn’s heart rate. But certain beta blockers, particularly labetalol, are among the most commonly used blood pressure medications during pregnancy precisely because they are considered relatively safer than most alternatives. If you are on an ACE inhibitor and become pregnant or plan to, your doctor will almost certainly switch you to a different class.

What Happens If You Stop Suddenly

Neither class of drug should be stopped abruptly without medical guidance, but the risks differ. Suddenly discontinuing a beta blocker can trigger what is sometimes called rebound sympathetic activity: the heart speeds up, blood pressure spikes, and in people with underlying coronary artery disease, this surge can provoke chest pain or even a heart attack. The risk is highest with high-dose beta blockers and when they are combined with other blood pressure medications.¹⁵ This is why beta blockers are typically tapered over a week or two rather than stopped cold.

ACE inhibitors do not produce the same kind of dramatic rebound, but stopping them abruptly still removes the cardiovascular protection they provide. Blood pressure will gradually rise back to its untreated level. If you are taking an ACE inhibitor for heart failure, stopping suddenly can allow fluid to build up again and symptoms to return. The general rule for both drug classes: talk to your prescriber before making changes.

Interactions with Common Pain Relievers

Both beta blockers and ACE inhibitors can have their blood-pressure-lowering effects blunted by common over-the-counter pain medications, specifically nonsteroidal anti-inflammatory drugs like ibuprofen and naproxen. NSAIDs inhibit the production of prostaglandins, which play a role in how both drug classes lower blood pressure. Research has found that indomethacin, a prescription NSAID, reduced the blood-pressure-lowering effect of the ACE inhibitor enalapril by about 45%.¹⁶

A post-marketing surveillance study confirmed that the effectiveness of ACE inhibitors, beta blockers, diuretics, and calcium channel blockers was all attenuated when patients were also taking NSAIDs, though the size of the effect varied by drug class.¹⁷ If you take a blood pressure medication from either class and regularly use ibuprofen or similar painkillers, your blood pressure control may be worse than expected. Acetaminophen is generally a safer alternative for occasional pain relief in this situation, though it is not entirely free of blood pressure effects either.

When an ACE Inhibitor Does Not Work Out

The ACE inhibitor cough drives a lot of patients to a closely related drug class called angiotensin receptor blockers, or ARBs. ARBs block angiotensin II from a different angle. Instead of preventing its creation, they block the receptor it binds to. The practical result is similar blood pressure lowering, but with an incidence of cough and angioedema comparable to placebo.¹⁸

A systematic review comparing the two found that ACE inhibitors and ARBs lower blood pressure about equally, but ACE inhibitors appeared slightly superior at reducing cardiovascular events and all-cause mortality. ARBs, however, were better tolerated overall.¹⁹ So the tradeoff is real: ACE inhibitors may have a small edge in protection, but that edge disappears if the cough causes you to stop taking the drug altogether. A medication you actually take consistently will always beat one you abandon.

Beta Blockers Beyond the Heart

One of the more interesting aspects of beta blockers is how many non-cardiac conditions they treat. Because they dampen the body’s stress response broadly, they have found roles well outside cardiology. Propranolol is a first-line therapy for essential tremor and is one of the most effective medications for preventing migraines. Timolol and metoprolol are also used in migraine prevention.²⁰ Propranolol is widely prescribed for performance anxiety, helping musicians, public speakers, and others manage the physical symptoms of stage fright like a racing heart and shaky hands. It is also the standard treatment for infantile hemangiomas, a type of benign blood vessel tumor in babies. Timolol eye drops are a mainstay of glaucoma treatment, lowering pressure inside the eye.

ACE inhibitors do not have the same breadth of off-label uses, though their ability to protect the kidneys and reduce protein in the urine has made them useful beyond pure blood pressure control in people with diabetic kidney disease.

From Snake Venom to Pharmacy Shelves

The origin story of ACE inhibitors is one of the more striking tales in drug development. Captopril, the first ACE inhibitor, was developed from research on peptides found in the venom of a Brazilian pit viper. Researchers discovered that components of the venom inhibited the angiotensin-converting enzyme, leading to a dramatic drop in blood pressure. That finding was refined into captopril, approved by the FDA in 1981, and eventually spawned an entire drug class.²¹ Beta blockers have a less exotic history but were equally revolutionary. Propranolol, introduced in the 1960s, was the first clinically successful beta blocker and earned its developer, James Black, a Nobel Prize. Between them, these two drug classes transformed the treatment of heart disease and high blood pressure in the second half of the twentieth century, and both remain foundational medications decades later.